Explore Stanford technologies available for licensing:

Researchers in Prof. Crystal Mackall's laboratory at Stanford University are focused on translational research related to cancer immunotherapy, including basic T-cell function and tumor immunology.

Stanford scientists in Dr. Michael Lin's lab have established the use of B-cell reducing agents to improve an oncolytic virus (OV) therapy to rewire cancer signaling while limiting the production of antibodies against the virus in mouse studies.

Stanford scientists have developed a novel calibration method to improve the accuracy and sensitivity of CRISPR-based diagnostic assays.

Researchers at Stanford have discovered a therapeutic strategy to overcome off-target red blood cell (RBC) toxicity associated with anti-CD47 antibody cancer therapies and possibly antibody-mediated autoimmune anemia and thrombocytopenia.

Heart failure is a complex cardiovascular disease that affects 26 million people worldwide and is characterized by the inability of the heart to pump blood effectively, leading to a decline in its normal functions.

Stanford researchers have developed a method of reducing pulmonary hypertension (PH) in mammals by targeting FHIT (Fragile Histidine Triad), a gene not previously linked to PH but consistently reduced in blood of patients with pulmonary arterial hypertension (PAH).

Stanford scientists have developed a platform that combines Raman spectroscopy, nanomaterials, and machine learning to rapidly identify bacteria in wastewater without chemical labels.

Disease indication:

CT imaging and MR imaging are two essential and widely used techniques for diagnostics. Currently, the two imaging techniques are performed sequentially, which is time-consuming and prone to errors due to anatomical changes that occur between the scans.

Researchers at Stanford and WashU developed cannabinoid receptor agonists with distribution mainly to peripheral tissues. Cannabinoid agonists are relevant for treatment of many indications, but current clinical use is limited by a variety of side effects.

Stanford researchers in the KC Huang Lab have patented a method that identifies functionally conserved protein regions with recurrent genomic alterations in cohort studies using natural variations in genomic sequences, which allows for the discovery and further understanding o

Stanford researchers have developed novel ENPP1 and ENPP3 inhibitors for cancer immunotherapy. ENPP1 inhibitors have previously been reported but ENPP3 is a newly discovered target.

PRFlpo CRISPR-derived knock-in mice are designed to have 2A-flpo sequence inserted into the 3' UTR of the progesterone receptor (Pgr) gene.

Esr1Flpo CRISPR-derived knock-in mice are designed to have 2A-flpo sequence inserted into the 3' UTR of the estrogen receptor 1 (alpha) (Esr1) gene.

Stanford scientists have developed an innovative 3D brain organoid culture system derived from adult neural stem cells to model neurodegenerative diseases like Alzheimer's and enable high-throughput drug screening.